In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi-center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ ) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event-acute splenic sequestration (ASS), vaso-occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death-was used as a composite endpoint. Infants were recruited at a mean age of 4.4 AE1 months. Median follow-up was 19.4 months.
(HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or Υ-globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11-0.73) and 0.16 (0.06-0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.
| INTRODUCTION
Sickle cell anemia (SCA), although a long described monogenic disorder, remains a severe disease with an unpredictable course. The first months of life are a time with a low incidence of complications, a state attributable to the sustained level of protective fetal hemoglobin (HbF). HbF has a pivotal anti-polymerization effect on the mutant hemoglobin (HbS). As the physiological switch from HbF to HbS progresses, increased polymerization of HbS occurs, resulting in multiple and inter related downstream effects: vaso occlusion, hemolysis, inflammation, increased cell adhesion, endothelial dysfunction and decreased function of NO. These changes are likely to play a role in the observed marked variability in the manifestations of both acute complications and progressive organ damage in infants as they age.
In high-income countries, generalized neonatal screening has led to a drastic decline in SCA-related mortality in very young children through the implementation of penicillin prophylaxis, immunization, parental education, cerebral vasculopathy screening and improved medical care
1 . Yet, complications such as acute splenic sequestration (ASS), dactylitis, acute anemia, acute chest syndrome (ACS), severe invasive infection, and central nervous system injury remain prevalent and unpredictable 2 .
Numerous studies have attempted to define biomarkers associated with disease severity or clinical outcomes with a predominant focus on adults and/or using either a retrospective or cross-sectional study design 3 . Many of these studies were performed before the implementation of newborn screening and of prophylactic programs.
Furthermore, the studies employed a wide variability in the definition of clinical severity and of outcomes. Indeed, contradictory results have been found regarding diverse markers of severity, such as the predictive value of HbF. In fact, validated prognostic markers are still lacking for identification of children at high risk, particularly in early infancy 4 .
Need for such identification is becoming increasingly important as more therapeutic and curative options are being developed 5, 6 . The goal of the present longitudinal study was to identify clinical, biological or genetic parameters early in infancy, before the onset of complications that could predict severe outcomes in the first 2 years of life.
An additional objective was to describe longitudinally the natural history and the evolution of specific biomarkers in a cohort of SCA newborns by regular and frequent monitoring during the first 2 years of life.
| METHODS

| Study design and subjects
A prospective study (ClinicalTrials.gov: NCT01207037) was set up at five participating centers. The primary objective was to determine prognostic factors predicting severe SCA-related events within first 2 years of life in SCA infants. Inclusion criteria were: (1) SS or S-β sickle genotype; (2) Age less than 6 months; (3) No prior episode of ASS. Due to the exploratory nature of the study, no sample size was predetermined, but a target number of 60 infants was established, based on the expected number of SCA newborns referred to these centers during the inclusion period (around 120 newborns) and an estimated 50% acceptance rate. The study was offered to all infants meeting the inclusion criteria in the participating centers during the inclusion period.
After informed consent was obtained, patients in the study were followed with scheduled visits planned at enrolment (3 and/or 6 months), 12, 18 and up to 24 months. All received standard ageappropriate care for SCA, with no modification of access to care or medication in relation with the study 7 . The protocol was approved by the ethics committee "Comité pour la Protection des Personnes Ile de
France II" and by the French agency for security of health products (AFSSAPS). .
| Endpoints and monitoring
A VOC event was defined as pain in the extremities, back, abdomen, chest, or head for which no other explanation could be found. 3 | RESULTS
| Statistical analysis
| Study participants
Between December 2010 and March 2013, 114 children with a neonatal diagnosis of SCA were referred to five investigating centres in the Paris area. A total of 57 infants (SS n = 55; Sβ n = 2; 54.4% males) were included in the study and followed for a median of 19.4 months (range 3.1-23.2). Two infants dropped out at 6 months because parents withdrew their consent and two were lost to follow up at 6.6 and 7.9 months respectively.
| Patient characteristics at inclusion
Major clinical, genetic and biological characteristics at inclusion are summarized in Table 1 and Supporting Information Table 1 .
Median age at inclusion was 4.4 months [3.4-5.2]
. A history of a medical event was reported in 9 (16%), including prior hospitalization in 5 (8.5%). Only one event however was related to SCA (dactylitis), other events were infectious (bronchiolitis n = 2; isolated fever n = 1, diarrhea n = 1). Growth parameters were normal: 6.6 kg [5. There was an early alteration of deformability parameters (low DI, O min and O 0 ) in this young cohort, when compared to normal controls 12 and a substantially elevated % of both the dense reticulocyte and mature red cell sub populations. A specific profile of expression of erythroid markers on reticulocytes and mature red cells was noted and is detailed in the paragraph "Analysis of longitudinal data". 
| Clinical course in infancy
| Early prognostic factors of disease severity
Clinical, genetic and biological parameters at enrollment (4 months)
were analyzed for their prognostic value and the results are summarized in Table 2 :
When combining all severe outcomes, univariate analysis of data at enrollment showed that the most powerful protective factor was increased HbF levels, whether in % or concentration (P < 0.001) or Fcells % (P < 0.05). Furthermore, protective thresholds of HbF levels were identified: HbF% >33.5% on enrollment, the hazard ratio (95% CI) for an adverse event was 0.24 (0.09-0.58) (P < 0.001), and HbF concentration >2.8 g/dL (HR (95% CI) = 0.11 (0.04-0.27), P < 0.001).
Likewise 
| Early prognostic factors of ASS
Univariate analysis showed that higher HbF (whether in % or concentration) was the strongest protective parameters for ASS (P < 0.001) with a significant threshold of 33.5% or 2.8 g/dL, respectively. 
| Early prognostic factors for VOC events
Regarding VOC events, univariate analysis of data at inclusion showed that low Hb level (<8 g/dL), and % high dense cells correlated with the occurrence of a VOC event (P = 0.004 and 0.018, respectively). Conversely HbF levels at 4 months (whether in %, concentration or F-cells %) were not predictive. Likewise, the HbF genetic score did not influence VOC outcome. However, 10 patients (20%) had an enlarged spleen at 2 years of age and at least 19 patients (33.3%) experienced palpable splenomegaly at some point during the study period.
| Biological data
The present study allowed us to establish longitudinal trends for conventional and SCA-specific laboratory parameters during the first , in infants it might be expected that most of the variation in HbF levels is caused by genetic factors, with relatively less variation due to acquired and environmental factors.
We therefore tested a previously validated score g(HbF), representing the genetic component of % HbF
19
. A very strong correlation with HbF production after 6 months of age was noted. Interestingly, the major (and only) contributor to such correlation was the BCL11A rs1427407 variant. However, the score failed to have a prognostic value for severe clinical outcomes as did, predictably, each of the variants analyzed, including BCL11A rs1427407. The lack of correlation of this genetic score with clinical outcomes in our cohort may relate to the differences in genetic background and age of the cohorts in which the score was initially validated, and additional genetic determinants may be of importance. However, this result also strongly suggests that nongenetic determinants of HbF are important in modulating clinical severity, even in very young children. 26 and more generally adhesion molecules failed to provide prognostically significant insights in our study. Regarding reticulocyte and leucocyte counts, differences in study design might account for these discrepancies 27, 28 . Regarding adhesion molecules, the reason for not being able to document such effects in the present study may be related to the fact that our measurements were performed at 4 months of age, there is free healthcare access to all. These high figures therefore should not be influenced by the fact that these infants were in a study and families more cautious. Notwithstanding hospital admissions, when specifically considering SCA-related events, 22 (38.6%) babies had experienced at least one severe event by 24 months. This data is consistent with the hospitalization rate reported in the nontreated arm of the BABY HUG trial 30 . In contrast, no ACS was reported in our cohort as opposed to 27 events, a discrepancy possibly related to the older age of the BABY HUG cohort (mean age at enrollment: 13Á5
AE2Á8 months) with ACS occurring at a median age of 27 months (12-39). Altogether, these results demonstrate the persistently high and early burden of SCA in very young children screened at birth and followed up in a socio economically privileged setting.
Screening tools to select patients at high risk for complications remains a challenge in SCA management. Our study demonstrates the ability of HbF measured in the first months of life to robustly predict disease severity. Following the BABY HUG trial 31 , hydroxycarbamide, which increases HbF level, was recommended for all SCA infants starting at 9 months of age, regardless of clinical severity 32 .
Our data also argues for an early use of HbF inducing agents as a disease modifying treatment because a very large fraction of SCA infants will experience a severe complication in the first 2 years of age, because red cells are markedly abnormal by the age of 4 months, and because a low level of HbF is a strong marker of short-term severity.
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